High-throughput identification of factors promoting neuronal differentiation of human neural progenitor cells in microscale 3D cell culture


Abstract
Identification of conditions for guided and specific differentiation of human stem cell and progenitor cells is important for continued development and engineering of in vitro cell culture systems for use in regenerative medicine, drug discovery, and human toxicology. Three-dimensional (3D) and organotypic cell culture models have been used increasingly for in vitro cell culture because they may better model endogenous tissue environments. However, detailed studies of stem cell differentiation within 3D cultures remain limited, particularly with respect to high-throughput screening. Herein, we demonstrate the use of a microarray chip-based platform to screen, in high-throughput, individual and paired effects of 12 soluble factors on the neuronal differentiation of a human neural progenitor cell line (ReNcell VM) encapsulated in microscale 3D Matrigel cultures. Dose–response analysis of selected combinations from the initial combinatorial screen revealed that the combined treatment of all-trans retinoic acid (RA) with the glycogen synthase kinase 3 inhibitor CHIR-99021 (CHIR) enhances neurogenesis while simultaneously decreases astrocyte differentiation, whereas the combined treatment of brain-derived neurotrophic factor and the small azide neuropathiazol enhances the differentiation into neurons and astrocytes. Subtype specification analysis of RA- and CHIR-differentiated cultures revealed that enhanced neurogenesis was not biased toward a specific neuronal subtype. Together, these results demonstrate a high-throughput screening platform for rapid evaluation of differentiation conditions in a 3D environment, which will aid the development and application of 3D stem cell culture models.

KEYWORDS
Differentiation, high-throughput screening, human neural progenitor cells (hNPCs), neurogenesis, three-dimensional (3D) cell culture

1 | INTRODUCTION
The controlled differentiation of human stem cells and progenitor cells is important for efficient derivation of specific cell types for a wide range of applications including regenerative medicine, drug discovery, generation of in vitro cell-based models, and toxicity screening (Breier et al., 2010; Choi et al., 2014; Gonzalez et al., 2013). While advances have been made toward these goals, identifying specific differentiation conditions (i.e., media additives, duration of exposure, concentration, time of onset, etc.) continues to be a rate- and efficiency-limiting factor in stem cell applications. This challenge is due to the complexity of stem cell differentiation, which depends on orchestrated changes in the gene
expression mediated by both intrinsic and extrinsic signals within complex networks (Gupta et al., 2010). Compounding this complexity is the large combinatorial sampling space between testable conditions and differentiation endpoints, which may be addressed through high-throughput screening to interrogate, understand, and control stem cell differentiation (Desbordes et al., 2008; Rhim et al., 2015; Underhill & Bhatia, 2007). Such studies are made even more complex when three-dimensional (3D) cultures are considered, as the enhanced cell-cell and cell-extracellular matrix (ECM) interactions associated with the 3D cultures may further alter cellular responses to soluble stimuli. For example, Yang et al. (2010) found that changing the encapsulating matrix altered directed differentiation outcomes of 3D encapsulated embryonic stem cells. There is, therefore, an important need to screen and optimize differentiation protocols, particularly for emerging 3D cell cultures, yet high-throughput screening of 3D cell cultures, including studies of stem cell differentiation, has only recently begun to emerge (Nierode et al., 2016; Ranga et al., 2014).

Stem cell-derived 3D neuronal cultures have gained particular interest because they have demonstrated utility in modeling neurological and neurodegenerative disorders (Choi et al., 2014; Jang et al., 2014). For example, by culturing human neural progenitor cells (hNPCs) overexpressing genes associated with familial Alzheimer’s disease within 3D Matrigel, Choi et al. (2014) were able to create an in vitro model that recapitulates the hallmark pathology of Alzheimer’s disease. Three-dimensional neuronal models are also attractive because they may offer improved scalability of stem cell production for regenerative medicine, such as dopaminergic neurons for Parkinson’s disease (Adil et al., 2017; Lei & Schaffer, 2013).

Herein, we use a microarray chip platform, previously developed for high-throughput toxicity screening, to assess the impact of 12 soluble differentiation factors, individually and in combination, on a 3D neuronal differentiation of a MYC immortalized hNPC (ReNcell VM) line. Immunofluorescence-based analysis of a neuron-specific protein marker, β-III tubulin (TUBB3), led to the identification of several soluble factors and their combinations that enhanced neuronal differentiation. Further investigation of selected combinations provided preliminary insight into the effects of specific soluble factor combinations on neural progenitor cell fate and neuronal subtype specification. Finally, we explored the impact of 3D culture scale (1,000-fold increase) on guided hNPC differentiation under conditions that enhanced neuronal differentiation in microscale 3D culture. Together, the results of this study demonstrate the use of a microarray-based cell culture platform for rapid, high-throughput screening of 3D stem/progenitor cell differentiation, which is crucial for the accelerated development of improved stem cell-derived 3D and organotypic cell culture models.

2 | MATERIALS AND METHODS

2.1 | hNPC culture

The MYC immortalized hNPCs line ReNcell VM (EMD Millipore) was used in this study at between passages 4 and 8. Undifferentiated hNPCs were maintained by culturing on laminin (Sigma) coated T25 or T75 flasks in complete growth medium, consisting of ReNcell Maintenance Medium (EMD Millipore) containing 20 ng/ml fibroblast growth factor 2 (FGF2) (EMD Millipore), 20 ng/ml epidermal growth factor (EGF) (EMD Millipore), and 100 U/ml penicillin-streptomycin (Gibco). Cells were passaged using Accutase and replated at 10,000 cells/cm² when approximately 90% confluent. The medium was changed the day after passing and every second day after that.

For off-chip 3D culture, freshly passaged undifferentiated ReNcell VM were mixed with Matrigel (high concentration growth factor reduced, corning) at such a ratio that the final cell concentration was 5 × 10⁶ cells/ml and the final Matrigel concentration was 1% (w/v). Hundred microliters of this cell-Matrigel suspension (containing 500,000 cells) was seeded into eight-well chamber microscope slides (Nunc) and incubated at 37°C for 15 min to gel. After, 400-μl media was added and exchanged every second day. All cultures were maintained within incubators at 37°C and 5% CO₂.

2.2 | Three-dimensional microarray culture preparation

Polystyrene micropillar and microwell chips (MBD Korea Co., Seoul, South Korea) were used for on-chip culture and screening. Before use, the polystyrene chip surface was coated with a polydopamine substrate as outlined by Lee, Dellatore, Miller, & Messersmith (2007); Lee, Rho, & Messersmith (2009), to enable covalent attachment of the Matrigel spots. Briefly, chips were incubated in a solution of 2 mg/ml dopamine (Sigma) in 10 mM tris-base at pH 8.5 for 2 hr at room temperature (RT) on an orbital shaker at 120 rpm. The chips were then rinsed with sterile deionized water and air dried in a sterile laminar flow hood. Before use, the microwell chips were exposed to UV (302 nm; 9 cm from source) for 4 hr using a 96 W transilluminator (Syngene GVM-30) to reduce surface hydrophobicity, as outlined by Kohen, Little, & Healy (2009).

On-chip 3D cultures were prepared using an enclosed MicroSys 5100-4SQ (DigiLabs) noncontact robotic microarray liquids dispensing system with a cooling head modification, as described previously (Nierode et al., 2016). In short, 850 nl of complete growth media was printed into the microwell chips, covered with gas permeable sealing membranes (Diversified Biotech) and stored in an incubator (37°C and 5% CO₂). Cooled suspensions of newly passaged ReNcell VM were mixed with Matrigel (high concentration growth factor reduced, Corning) in a ratio such that the final cell concentration was 5 × 10⁶ cells/ml with a final Matrigel concentration of 1% (w/v) and kept on ice. The cooled microarray system was then used to spot 100 nl of Matrigel-cell mixtures onto the pillars of the micropillar chip (approximately 500 cells within each spot). After printing, the 3D culture-laden micropillar chips were incubated for 15 min at 37°C in a humid chamber to polymerize Matrigel and stamped into a microwell containing warmed media. Cultures were stored in a humidified chamber within an incubator (37°C and 5% CO₂) and media was exchanged every second day (by stamping to a new microwell chip).
For differentiation screening, on-chip cultures were prepared and undifferentiated hNPCs allowed to expand for 5 days in complete growth medium. On the fifth day, on-chip cultures were switched to ReNcell maintenance media supplemented with 100 U/ml pen-strep without EGF and FGF2 containing the 12 differentiation factors added individually or in paired combinations at the concentrations listed in Supporting Information Table S1. Vendors for differentiation factors are also listed in Supporting Information Table S1. All media was supplemented to a final concentration of 0.5% (v/v) dimethyl sulfoxide during differentiation, which was used as a carrier for retinoic acid (RA), CHIR-99021 (CHIR), PURM, NPZ, and FORS. Following 5-day exposure to differentiation factors, cultures were maintained in ReNcell maintenance media for five additional days before immunofluorescence-based processing and analysis.

2.3 | In-cell immunofluorescence assays

On-chip 3D cultures were rinsed with warm Dulbecco’s phosphate buffered saline (DPBS) and fixed with 4% (w/v) formaldehyde and 0.25% (w/v) glutaraldehyde in DPBS for 20 min at RT. Fixed cells were permeated with 0.25% (v/v) Triton X-100 in DPBS for 10 min, rinsed with DPBS, and quenched for 30 min in distilled water containing 2 mg/ml sodium borohydride (Sigma). Cells were blocked overnight at 4°C in DPBS with 5% (w/v) bovine serum albumin (BSA) and 1% (v/v) goat serum and incubated in primary antibody solutions diluted into DPBS containing 1% (w/v) BSA, 1% goat serum, and 10 ppm antifoam C (Sigma) overnight at 4°C. Cells were washed with DPBS three-times for 2 hr each before repeating the antibody incubation step with secondary antibodies. Antibody incubations were performed in 750 nl of antibody-containing solutions on-chip, and a complete list of primary and secondary antibodies, vendors, and dilutions used is presented in Supporting Information Table S3. After incubation with secondary antibodies, cells were washed with DPBS three-times for 2 hr each before 10 min incubation in DPBS with 5 µg/ml Hoechst 33342. Lastly, micropillar chips were rinsed with DPBS containing 50 mM trehalose for 10 min before being completely dried with nitrogen and stored in the dark. Dried micropillar chips were imaged using a ThermoFisher Cellomics ArrayScan VTI automated fluorescent microscope, and images were processed using the Cellomics analysis suite as described in further detail within the Supplementary Information.

2.4 | Western blot analysis

Cell lysate protein concentrations were estimated using a bicinchoninic acid (BCA) assay (Sigma). Equal amounts of protein (approximately 10 µg) were loaded into either 8% or 12% cast sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels. Gels were resolved at 120 V in a tris-glycine buffer and electro-transferred to a nitrocellulose membrane for either 60 min at 100 V (12% gel) or overnight at 30 V (8% gel) at 4°C. Membranes were rinsed with tris-buffered saline (TBS), blocked in 5% (w/v) BSA TBS for 1 hr at RT, and incubated overnight at 4°C in primary antibody solutions diluted in blocking buffer with 0.05% (v/v) Tween-20. Membranes were rinsed with TBS containing 0.05% Tween-20 (TBST) and incubated with an appropriate secondary antibody diluted in TBS with 3% BSA for 90 min at RT. Membranes were washed with TBST and then TBS before incubation with chemiluminescence solution (SuperSignal Pico, Pierce) for 10 min. Membranes were imaged with a Bio-Rad ChemiDoc and subsequently stripped using a stripping buffer (200 mM glycine; 1% (v/v) Tween-20; 0.1% (w/v) SDS; pH 2) and evaluated for efficient stripping with chemiluminescence before being reused with the above procedure for detection of loading control proteins (GAPDH for 12% gels, Vinculin for 8% gels).

3 | RESULTS AND DISCUSSION

3.1 | Neuronal differentiation screening of hNPCs in 3D Matrigel

Twelve soluble differentiation factors and small molecules reported to enhance 2D neuronal differentiation were identified from the literature and used as a guide to investigate, in high-throughput, their individual and paired effects on 3D neuronal differentiation of ReNcell VM hNPCs. The library encompasses both synthetic small molecules and endogenous proteins and signaling factors involved in modulating in vitro neuronal differentiation (Supporting Information Table S1). Within the 12-member library, six compounds were small molecules, including all-trans RA, neuropathiazol (NPZ), CHIR, dibutyryl cyclic adenosine monophosphate, forskolin (FORS), and purmorphamine (PURM). The other six factors consisted of growth factors and secreted proteins that provide signaling and trophic support during and after neuronal differentiation including the glial-derived neurotrophic factor, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT3), neuregulin-1β (NRG1), FGF8, and transforming growth factor β-3. The aim of this initial screen was to rapidly identify conditions that enhanced a neuronal fate for subsequent analysis. The concentrations screened were based on values reported in the literature to be bioactive (Supporting Information Table S1).

A dual microarray chip platform was used for the 3D differentiation screen, as recently demonstrated for high-throughput/high-content phenotypic screening of 3D cultures (Supporting Information Figure S1) (Nierode et al., 2016). This platform consists of two complementary polystyrene “chips” that have either 532 micropillars (micropillar chip) or microwells (microwell chip). Three-dimensional cell cultures (100 nl) atop micropillar chips are “stamped” with microwell chips containing media (e.g., 850 nl) for on-chip culturing and screening. Undifferentiated ReNcell VM hNPCs were embedded within 100 nl 1% (w/v) Matrigel spots (500 cells/spot) on each pillar and expanded before being induced to differentiate by simultaneously removing EGF and FGF2 and adding various combinations of differentiation factors for five days. The cultures were then matured for five additional days before analysis (Figure 1a). High-content, on-chip immunofluorescence-based analysis of TUBB3 expression (Figure 1b), an early neuron-specific protein marker, was used to
FIGURE 1  Individual and combined effects of 12 soluble differentiation factors on TUBB3 expression within microscale 3D hNPC cultures. (a) Three-dimensional hNPC differentiation screen schematic. (b) Representative immunofluorescence-based images used for high-content analysis of 3D hNPC differentiation outcomes. Chosen images depict antibody-based detection of TUBB3 expression (green) and Hoechst 33342-based detection of cell nuclei (blue) for the no primary antibody control, conditions which increased the relative TUBB3 expression (CHIR+RA and PURM+RA), and the spontaneous (no factors added) control. Scale bar = 300 µm. (c) The average Hoechst 33342 normalized TUBB3 expression from n = 12 collected from three independent screens is plotted for each condition tested. Mean ± SEM plotted. (d) Log$_2$ heat map of TUBB3 expression relative to spontaneous differentiation. Three replicate screens were performed and the log$_2$ relative fluorescence of each screened condition was normalized by that of the spontaneous differentiation. To elucidate the influence of individual and combination treatments, the log$_2$ values were used to generate a heat map by correlating values to a color gradient between the minimum (red) and maximum (green) values. (e) Select conditions from 3D hNPC neuronal differentiation screen. One-way ANOVA analysis of the Hoechst 33342 normalized TUBB3 expression identified several conditions that resulted in statistically significant different TUBB3 expression compared with the spontaneous differentiation control (p < 0.05, **p < 0.01, and ***p < 0.0001). Mean ± SEM plotted. 3D: three-dimensional; ANOVA: analysis of variance; CHIR: CHIR-99021; hNPC: human neural progenitor cell; PURM: purmorphamine; RA: retinoic acid; SEM: standard error of the mean; TUBB3: β-III tubulin [Color figure can be viewed at wileyonlinelibrary.com]
that in our screen the RA treatment alone was not identified as significantly different from spontaneous differentiation. In addition, paired combinations typically resulted in more TUBB3 expression in comparison to individual compounds. A one-way analysis of variance (ANOVA) of average TUBB3 expression and post hoc analysis (using Dunnett’s correction to account for multiple comparisons) identified 13 neuronal differentiation conditions that were statistically different (p < 0.05) from spontaneous differentiation (Figure 1c; Dunnett & Tamhane, 1992). Moreover, only paired combinations were significantly different from spontaneous differentiation, and 11 of the 13 significant combinations contained RA. Indeed, every combination containing RA resulted in significantly higher TUBB3 expression compared with spontaneous differentiation. Identification of RA as a strong inducer of neuronal differentiation was not surprising, as RA is well known to induce neuronal differentiation on multiple types of neural progenitor cells (Erceg et al., 2008; Janesick, Wu, & Blumberg, 2015; Takahashi, Palmer, & Gage, 1999). It was interesting, however, that in our screen the RA treatment alone was not identified as being statistically significant, but combined treatment of RA with other led to more pronounced effects, which is consistent with its differentiation-inducing effects reported in the literature (Encinas et al., 2000; Takahashi et al., 1999). In addition, apart from combinations with RA, significantly enhanced neuronal differentiation, as reflected in enhanced TUBB3 expression, was also observed for PURM+CHIR and BDNF+NPZ (Figure 1c). As with RA alone, individual components in these two pairs did not lead to significant increases in TUBB3 expression (Figure 1c). Overall, this initial screen provided a rapid assessment of conditions on their ability to promote neuronal differentiation and identified several interesting conditions for subsequent analysis.

3.2 | Dose–response effects of select conditions on 3D Matrigel hNPC differentiation

The strength of biological signals can alter cellular responses and differentiation outcomes. Thus, we proceeded to examine the dose dependence of select media combinations on hNPC differentiation in 3D Matrigel. The screen was performed in a 2^4 factorial design, wherein the concentration of each component of the chosen combination was varied at four levels (no compound, and respectively low, medium and high concentrations). Expression of six cell-type specific protein markers was investigated to characterize more broadly the dose-dependent effects of the chosen combinations on 3D hNPC differentiation outcomes following a 10-day differentiation as outlined in Figure 1a. Neuronal differentiation was assessed by expression of both the early neuronal marker TUBB3 and the more mature neuronal protein marker microtubule-associated protein 2B (MAP2B), thereby providing an opportunity to assess the extent of neuronal differentiation (Menezes & Luskin, 1994). Expression of tyrosine hydroxylase (TH), an enzyme required for biosynthesis of dopamine, was quantified to evaluate specific differentiation into dopaminergic neurons (van den Pol, Herbst, & Powell, 1984). The ReNcell VM line, a nonclonal MYC (v-myc) immortalized cell line derived from human ventral mesencephalon tissue, is a heterogenous mixture of neural progenitors at various stages of development and is known to differentiate toward a dopaminergic fate because of its location in the brain (Donato et al., 2007; Rhim et al., 2015). As with early and late neuronal differentiation, glial differentiation was characterized by expression of the glial fibrillary acidic protein (GFAP), an early astrocytic marker, and the calcium-binding protein S100β, expressed in mature astrocytes (Raponi et al., 2007). Lastly, expression of nestin (NES), an intermediate filament expressed in undifferentiated NPCs and immature neural cells, was measured to assess maturation from the progenitor stage (Dahlstrand, Lardelli, & Lendahl, 1995; Park et al., 2010).

Based on the initial screen, three combinations (RA+CHIR, BDNF+NPZ, and NRG1+NT3) were chosen for further analysis. The treatments of RA+CHIR (p < 0.0001) and BDNF+NPZ (p < 0.01) resulted in substantial and statistically significant enhancement of TUBB3 expression in comparison to spontaneous differentiation. Conversely, NRG1+NT3 reduced TUBB3 expression relative to NT3 or NRG1 alone.

3.2.1 | RA and CHIR

Increased expression of both neuron-specific proteins TUBB3 (two-way ANOVA; p < 0.10) and MAP2B (two-way ANOVA; p < 0.05) (Figure 2a; Supporting Information Table S2) was observed in differentiating cultures as a function of increased RA concentration. At 1 µM RA, TUBB3 expression increased nearly 1.5-fold over spontaneous differentiation, while MAP2B expression increased approximately 2-fold. Decreased MAP2B and TUBB3 expression at 2µM RA could suggest a narrow effective concentration range of RA on enhancing neuronal differentiation. This was not due to toxicity, as no loss in cell
viability was observed in the differentiating cultures at the concentrations tested (Supporting Information Figure S2). RA treatment alone did not impact TH expression. Notably, RA treatment was found to decrease the expression of GFAP beginning at 0.25 µM, S100β beginning at 1 µM, and NES beginning at 2 µM—all of which were supported by two-way ANOVA analysis (Figure 2a; Supporting Information Table S2). The decreased expression of astrocytic protein markers coinciding with increased expression of neuron-specific protein markers suggests that RA treatment biases 3D hNPC differentiation outcomes toward neuronal fates, which is consistent with previous literature reports in 2D culture (Takahashi et al., 1999).

Meanwhile, the decreased NES expression could signify a more rapid departure from the progenitor stage and is in agreement with the potent morphogenic activity of RA, which is an endogenous agonist of cellular RA receptor proteins that induces differentiation of many tissues, including terminal neural differentiation (Janesick et al., 2015).

The CHIR treatment alone was found to have a positive effect on the expression of TUBB3 and MAP2B, which was supported by two-way ANOVA analysis (Figure 2b; Supporting Information Table S2). The CHIR treatment also decreased the GFAP expression, although this effect was only evident at 4 µM CHIR. In addition, there was a positive trend between CHIR concentration and expression of S100β and NES (Figure 2b). As with RA, CHIR did not have a substantial effect on TH expression. Taken together, these results suggest that CHIR has complex effects that are difficult to delineate within a heterogeneous mixture of neural progenitors (including multipotent,
glial, and neuronal-restricted progenitors). CHIR, a small molecule inhibitor of glycogen synthase kinase 3, activates the canonical Wnt signaling, which is important for both maintenance and differentiation of neural progenitor cells during development (Andersson et al., 2013; Arenas, 2014; Metcalfe & Bienz, 2011; Wu & Pan, 2010). Based on our results, the CHIR treatment appears to increase the proportion of ReNcells differentiating toward neurons (increased TUBB3 expression) and enhance neuronal maturation (increased MAP2B expression).

In addition, stable and eventually decreased GFAP expression suggests that CHIR inhibits the differentiation toward astrocytes and that increased S100B expression could be a result of indirect enhanced astrocyte maturation due to Wnt-mediated neurogenesis, as observed by Kasai, Satoh, and Akiyama (2005). Specifically, Wnt-mediated neuronal differentiation may result in Notch activation, which is involved in regulating glial differentiation as well as maintenance of progenitor pools (Nusse et al., 2008). Thus, the increased NES expression observed at higher CHIR concentrations may also be an indirect effect of CHIR inducing a subset of neural progenitors toward a neuronal fate (Chenn, 2008; Formosa-Jordan, Ibanes, Ares, & Frade, 2012). Moreover, it is likely that FGF2 removal from the 3D matrix (following removal from the medium) is gradual because Matrigel contains heparan sulfate (HS) proteoglycans, which have a high affinity for FGFs (Akashi et al., 2005; Tsilibary et al., 1988). Indeed, Matrigel simultaneously decreases the diffusivity of FGF2 across a porous membrane and entraps soluble FGF2 within its matrix in a process that is attenuated by soluble HS (Dabin & Courtois, 1991; Dowd, Cooney, & Nugent, 1999). Moreover, HS is a component of the basal ReNcell medium. Therefore, the increased expression of NES observed at higher CHIR concentrations may be a result of residual FGF2 in the 3D microenvironment.

The combinatorial effects of RA and CHIR on differentiation outcomes were also evaluated to identify interaction effects between the compounds. Based on our initial screen, we expected combined treatments of RA and CHIR to further enrich the expression of TUBB3 and MAP2B relative to treatments with RA or CHIR alone. While this was largely observed, trends to this effect were somewhat inconsistent (Figure 3). For example, the combination of 1µM RA and of 4µM CHIR led to nearly 30% higher expression of TUBB3 compared with 1µM RA treatment alone. However, there was no clear trend in TUBB3 expression with increasing CHIR concentration in the presence of RA. Unlike TUBB3 expression, the combined effects of RA and CHIR on MAP2B expression resembled the trends observed for RA and CHIR individually (Figure 3).

Combined RA and CHIR treatment resulted in decreased GFAP expression. We observed CHIR treatment alone only had a measurable effect at 4µM while as described above, RA alone decreased GFAP expression at all concentrations tested. Thus, while higher concentrations of combined RA and CHIR were found to lead to even lower GFAP expression, the decrease is largely due to RA. The effect of combined RA and CHIR treatment on S100B expression was interesting because S100B expression in the presence of CHIR alone increased whereas it decreased in the presence of RA alone. When treated with both RA and CHIR, S100B expression decreased, which suggests that RA has a greater effect on S100B expression than does CHIR. NES expression followed a similar trend. These results suggest that RA and CHIR impact ReNcell VM differentiation in mechanistically distinct ways. Combined treatment of RA and CHIR resulted in CHIR potentiating the effects of RA at 1 and 4µM.
CHIR, as supported by two-way ANOVA analysis (Supporting Information Table S2). We also observed that select combinations (e.g., 0.25µM RA+1µM CHIR) increased expression of the dopaminergic neuron marker TH by nearly two-fold in differentiating 3D cultures of ReNcell VM (Figure 3). This result is consistent with literature reports that the Wnt signaling is a key facilitator of midbrain dopaminergic neuronal differentiation, and that these effects are closely connected with the strength of its signaling (Andersson et al., 2013; Joksimovic & Awatramani, 2014).

The selectivity of RA and CHIR treatment in directing differentiation toward the neuronal fates of 3D hNPC cultures was also evaluated using two distinct methods. First, the ratio of the percentage of TUBB3 positive cells divided by GFAP positive cells was compared, as determined using Cellomics software’s automated image analysis. As shown in Figure 4a, the addition of CHIR to RA increased the percentage of differentiated neurons (more green color), with the greatest effect observed with 2µM RA+4µM CHIR. These differentiated cultures consisted of approximately 60% neurons and approximately 10% astrocytes (Supporting Information Figure S4B and C). Taken into context with viability analysis, it is possible that some of this enrichment may be a result of neuronal induction and selective killing of astrocytes, since a reduction in viability was observed at this combined concentration (Supporting Information Figure S2). The 3D hNPCs grew and differentiated as interconnected cell aggregates, which can limit the accuracy of image fluorescence intensity gating (Supporting Information Figure S4A). Thus, in addition to this method, a ratio of immunofluorescence-based intensities...
intensity values of neuron-specific and astrocyte-specific protein markers (e.g., TUBB3, MAP2B and GFAP, S100B) was used to calculate a fluorescence-based ratio as an estimate of both fate commitment and maturation in response to treatment. The immunofluorescence-based expression of each marker was normalized by the spontaneous condition to account for differences in antibody affinity. Consistent with our compositional analysis, the addition of CHIR to RA enriched neuronal differentiation and maturation (darker green color), with the greatest effect observed with 2µM RA + 1µM CHIR (Figure 4d). These methods are not equivalent; image gating analysis provided an analysis of fate specification while immunofluorescence intensity analysis provides information on fate specification and maturation.

3.2.2 BDNF and NPZ

Based on our initial screen, we expected that the combined treatment of BDNF, an agonist of tropomyosin receptor kinase B (TrkB), and NPZ, a strong small molecule promoter of neuronal differentiation in rat hippocampal progenitor cells, would result in increased enrichment of neuron specific proteins (Segal, 2003; Warashina et al., 2006). However, the combined treatment of BDNF and NPZ resulted in expression profiles of TUBB3 and MAP2B that resembled those obtained from BDNF or NPZ treatment alone (see Supporting Information Table S2, Supporting Information Figure S5, Supporting Information Figure S6, and Supplemental Information). For example, the MAP2B expression increased with increasing the concentration of BDNF, but was unaffected by NPZ treatment (Supporting Information Figure S5, Supporting Information Figure S6). Similar results were obtained for NES, GFAP, S100B, and TH in that there were no consistent expression trends from combinations of BDNF and NPZ (data not shown).

Analysis of the selectivity between neuronal and glial fates revealed BDNF alone slightly enriched neuronal fates, but NPZ-enriched expression of glia specific protein markers (Figures 4b,e). Nonetheless, the composition of NPZ-differentiated 3D hNPC cultures was predominantly astrocytic (Supporting Information Figures S4C and Supporting Information S4F). This result was interesting in view of Warashina et al. (2006), who reported that 10µM NPZ increased the number of TUBB3 expressing cells in differentiating rat hippocampal neural stem cells while simultaneously decreasing the number of GFAP expressing cells, and this effect was stronger than 5µM RA. Based on our initial screen and subsequent analysis, our results suggest the pro-neurogenic effects of NPZ may be limited to rat or hippocampal cell sources, or the proneurogenic effects may be reduced in 3D microscale culture.

3.2.3 NT3 and NRG1

NT3, an agonist of TrkC, and NRG1, a secreted peptide with binding activity for ErbB-3 and ErbB-4 receptor tyrosine kinases, individually had minimal effects on the markers tested (Mei & Xiong, 2008; Segal, 2003). Only NES was negatively impacted by NT3 (Supporting Information Table S2, Supporting Information Figure S7, Supporting Information Figure S8, Supplemental Information). Based on our initial screen, it was expected that the combined treatment of NT3 and NRG1 would decrease the expression of neuronal specific protein markers relative to spontaneous differentiation based on our initial screen. While this was observed for TUBB3 at higher concentrations tested (10 and 100 ng/ml for NT3 and NRG1, respectively), consistent trends were not observed (Supporting Information Figure S8A). In addition, combinations of NT3 and NRG1 also significantly impacted NES expression (Supporting Information Figure S8B). However, analysis of differentiated 3D hNPC cultures revealed that combined treatments of NT3 and NRG1 resulted in an enrichment of neuronal fate over an astrocytic fate and was strongest in the presence of NRG1 with 50 ng/ml of NT3 (Figures 4c,f). Compositional analysis of these cultures revealed that they also remained predominantly astrocytic (Supporting Information Figures S4D and Supporting Information S4G). Together, our results suggest NRG1 treatment may be involved in a complex regulatory control of fate specification and preservation of an undifferentiated state.

3.3 Effect of RA, CHIR and their combination on 3D neuronal subtype specification

Combined treatment with RA and CHIR enhanced the neuronal differentiation, and the dose–dependent effects of combined RA and CHIR on TH expression indicated that their combination may be effective in guiding neuronal subtype specification, for example, subtype differentiation (Figure 3). Thus, we repeated the dose–response experiment of RA, CHIR and their combination to investigate their impact on neuronal subtype specification. Expression of vesicular glutamate transporter 2 (VGLUT2), choline acetyltransferase (CHAT), glutamic acid decarboxylase (GAD65), and TH was measured to assess how RA and CHIR impact specification toward glutamatergic, cholinergic, GABAergic, and dopaminergic neurons, respectively, as these are considered broad markers for these neuronal subtypes (Ichikawa, Ajiki, Matsuura, & Misawa, 1997; Todd et al., 2003; van den Pol et al., 1984; Zhao, Eisinger, & Gammie, 2013).

After differentiation, cultures were double-stained to assess the expression of TUBB3 and one of the noted neuronal subtype protein markers. The Hoechst-normalized fluorescence intensities of TUBB3 and each subtype marker were plotted (Supporting Information Figure S9), and a two-way ANOVA analysis was used to identify whether RA and CHIR treatment had any significant effects on generating specific neuronal subtypes (Table 1). Individual treatment with either RA (p < 0.0001) or CHIR (p < 0.0001) was found to significantly increase the TUBB3 expression, largely in agreement with our previous dose–response assessment (Supporting Information Table S2). However, a statistically significant interaction effect between RA and CHIR on TUBB3 expression was found during the subtype specification screen (Table 1), and CHIR was less effective at enhancing TUBB3 expression (Supporting Information Figure S9).
The experimental variance resulting in these minor differences is likely a result of the nonclonal, heterogeneous properties of the hNPC cell line and the undefined Matrigel matrix. As for the effects on neuronal subtype specification, we observed that RA alone significantly increased the expression of GAD65, VGLUT2, TH, and CHAT. Meanwhile, the CHIR treatment was found to increase the expression of GAD65, VGLUT2, and CHAT (Table 1; Supporting Information Figure S9), however, to a lesser extent than RA. Interactive effects that would enhance the expression of any of the subtype markers tested were determined not to be significant. Together, these results indicate that while RA and CHIR may be used to enhance the neuronal differentiation of mixed progenitors, they do not have a strong effect on biasing the subtype specification of the differentiating ReNcell VM by themselves. These findings appear to be consistent with the literature on RA induction of motor neuron development (Xiao et al., 2016), as well as the other predominant midbrain neuronal subtypes (Chatzi, Brade, & Duester, 2011; Cooper et al., 2010; Morales & Root, 2014; Root et al., 2016).

3.4 | Scaling-up 3D hNPC differentiation

To qualitatively determine whether results identified on-chip translate to larger (bulk) scales, we repeated the 3D differentiation experiment using the previously chosen select combinations (RA +CHIR, BDNF+NPZ, and NRG1+NT3) in well plates at a 3D matrix volume of 100 μl for a 1,000-fold scale up. The cell density was maintained constant between the on-chip and 3D bulk differentiation, but the ratio of cells to media could not be kept constant due to size restrictions of the well plate. On-chip differentiation consisted of a gel-to-media ratio of 1:8.5 (100 nl 3D culture in 850 nl of media) and 3D bulk differentiation was performed at a ratio of 1:4 (100 μl 3D culture in 400 μl of media). Western blot detection of TUBB3, GFAP, and β-actin (loading control) expression was used to analyze changes in protein expression during bulk 3D hNPC differentiation in the presence of select media additives relative to a spontaneous differentiation control (Supporting Information Figure S10).

Western blot densitometry analysis of TUBB3 expression after ReNcell VM differentiated in 100 μl 3D matrix cultures was qualitatively similar that observed in 100 nl 3D cultures within microscale chip-based cultures (Figure 5a). For example, at the microscale, RA, CHIR, and their paired combination resulted in increased TUBB3 expression relative to spontaneous differentiation, and the paired RA+CHIR had the strongest positive influence on TUBB3 expression. This was similarly observed in 3D bulk cultures (Figure 5a). BDNF treatment was also found to enhance the TUBB3

### TABLE 1 ANOVA analysis of the individual and combined effects of RA and CHIR on expression of neuronal subtype specific protein markers. Analysis of a dose–response factorial screen of RA, CHIR and combined treatments on expression of pan-neuronal (TUBB3), dopaminergic (TH), GABAergic (GAD65), cholinergic (CHAT), and glutamatergic (VGLUT2) protein markers from two independent screens, wherein each condition had three technical replicates per chip screen (n = 6 total replicates per condition and marker).

<table>
<thead>
<tr>
<th>Protein</th>
<th>RA p value</th>
<th>CHIR p value</th>
<th>RA×CHIR p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TUBB3</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td>0.002</td>
</tr>
<tr>
<td>TH</td>
<td>&lt;0.05</td>
<td>N.S.</td>
<td>N.S.</td>
</tr>
<tr>
<td>GAD65</td>
<td>&lt;0.001</td>
<td>&lt;0.05</td>
<td>N.S.</td>
</tr>
<tr>
<td>CHAT</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td>N.S.</td>
</tr>
<tr>
<td>VGLUT2</td>
<td>&lt;0.0001</td>
<td>&lt;0.001</td>
<td>N.S.</td>
</tr>
</tbody>
</table>

Note. ANOVA: analysis of variance; CHAT: choline acetyltransferase; CHIR: CHIR-99021; GAD65: glutamic acid decarboxylase; RA: retinoic acid; TH: tyrosine hydroxylase; TUBB3: β-III tubulin; VGLUT2: vesicular glutamate transporter 2.

### FIGURE 5 Western blot analysis of individual and combined effects of select factors on differentiation outcomes of 100 μl 3D Matrigel ReNcell VM hNPC cultures. (a) Densitometry analysis of western blot detection of (a) TUBB3 and (b) GFAP expression following 3D ReNcell VM differentiation in 100 μl of 1% Matrigel relative to the spontaneous (no factors added) condition. Mean ± SD plotted for n = 2 independent biological replicates. 3D: three-dimensional; GFAP: glial fibrillary acidic protein; hNPC: human neural progenitor cells; SD: standard deviation; TUBB3: β-III tubulin
expression in both microscale and bulk. There were also similarities in changes in GFAP expression between microscale and bulk (Figure 5b).

Specifically, NT3, CHIR, and RA+CHIR resulted in decreased GFAP expression at the microscale and bulk.

Some qualitative differences were also observed in GFAP expression between 3D microscale and 3D bulk. In 3D microscale (100 nl), NPZ treatment increased GFAP expression, but in bulk, NPZ treatment decreased GFAP expression relative to spontaneous differentiation (Figure 5b). In addition, RA treatment alone at the microscale resulted in decreased GFAP expression, yet the minimal effect on GFAP expression was observed in the 3D 100 μl cultures. Conversely, NRG1 and NT3 did not strongly influence GFAP expression at the microscale, yet in bulk, they decreased GFAP expression relative to spontaneous differentiation.

The higher variability observed in 3D bulk differentiation as compared with the chip may be a result of the increased diffusional limitations within the larger 3D matrix in the well plate experiments and the different experimental methodologies used, for example, immunofluorescence for the chip experiments and Western blot analysis for the well plate experiments. Nonetheless, qualitatively, these results suggest that the scale of 3D culture did not impact the neurogenesis process imparted by the addition of compounds but may impact astrocyte development. As indicated above, one possible cause for this scaling effect may be due to diffusional limitations at the larger scale. Our previous result with the HepG2 human hepatoma cell line showed enhanced diffusion of oxygen and/or nutrients at the microscale versus in 96-well plates (Meli, Jordan, Clark, Linhardt, & Dordick, 2012), and this is similar to that observed by Ranga et al. (2014). Thus, the bulk 3D cultures may have decreased oxygen levels, and Mutoh, Sanosaka, Ito, & Nakashima (2012) have demonstrated that decreased oxygen levels impact astrocyte differentiation in the developing brain through epigenetic modifications. The 3D microscale screening results are representative of conditions of minimal diffusional limitations on nutrients or oxygen and may, therefore, reflect a more direct indication of the effects of the tested components on 3D hNPC differentiation outcomes.

4 | CONCLUSIONS

Due to the improved physiological relevance of 3D cultures, it is expected that the use of 3D stem cell-derived culture models will continue to expand. Therefore, there is a demand for high-throughput cell culture screening platforms that can be used to investigate the differentiation of stem cells in 3D cultures to identify optimal differentiation conditions. Herein, we used a cell culture microarray platform to screen rapidly individual and combined soluble factors for enhanced neuronal differentiation of 3D ReNCell VM hNPC cultures. Multiple conditions were identified from this initial screen, and subsequent dose-dependent differentiation screening more broadly characterized the differentiation effects for three selected conditions (RA+CHIR, BDNF+NPZ, and NT3+NRG1). From these studies, we found that combined RA and CHIR treatment resulted in a substantial increased neuronal differentiation and a simultaneous decrease in astrocyte differentiation. Further investigation of RA and CHIR on neuronal differentiation revealed that their combination alone does not bias the subtype specification of differentiating neurons but may be a good lead for further differentiation optimization. For example, there is great interest in controlling stem cell differentiation through engineering the ECM composition and 3D spatial patterning (Gattazzo, Urciuolo, & Bonaldo, 2014; Ranga et al., 2014; Solanki et al., 2010), and combined interrogation of ECM and soluble effects may result in even more finely-tuned control over differentiation outcomes.

Upon scale up, we observed that RA+CHIR had a similar effect on neuronal differentiation in both 100 nl and 100 μl 3D cultures. Together, these results begin to assess how differentiation factors influence differentiation outcomes of hNPC when differentiated in 3D, while also demonstrating the application of a robust microarray-based platform capable of high-throughput and high-content characterization of 3D differentiation outcomes. This type of platform and screening approach will be useful for the development of and identification of specific conditions to improve the controlled differentiation of 3D stem cell cultures, which will enable their widespread use for applications such as drug discovery and toxicity screening.

ACKNOWLEDGMENTS

This study was supported by NIH (ES020903) and the New York State Stem Cell Science Program.

ORCID

Gregory J. Nierode http://orcid.org/0000-0002-8334-2908

David V. Schaffer http://orcid.org/0000-0002-9625-0121

Jonathan S. Dordick http://orcid.org/0000-0001-7802-3702

REFERENCES


**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.